Skin-penetrating peptide and method for using same

Patent metadata

Field	Value
Publication number	US-10858395-B2
Application number	US-201615759134-A
Country	US
Kind code	B2
Filing date	Sep 9, 2016
Priority date	Sep 10, 2015
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

The present disclosure is directed to providing a new skin-penetrating peptide, a fusion product with a biologically active substance bound using the same, a cosmetic composition containing the same and a pharmaceutical composition for external application to skin containing the same. The skin-penetrating peptide of the present disclosure is less likely to cause an immune response as compared to existing skin-penetrating peptides and exhibits remarkably improved skin permeability. Therefore, the biologically active substance can be effectively delivered through the skin, particularly through the stratum corneum.

First claim

The invention claimed is:

1. A fusion product comprising:
a skin-penetrating peptide consisting of a sequence of (X1)n-X2-(cysteine)-(X3)m,
wherein
n is an integer from 3 to 14,
m is an integer from 4 to 14,
each of X1 and X3 is independently arginine, lysine, or histidine, and
X2 is alanine, glycine, proline, tryptophan, phenylalanine, leucine, isoleucine, methionine, valine, arginine, or histidine,
wherein if m is 4, —(X3)m is —KRRR or —RRRR;

a biologically active substance selected from the group consisting of a protein, a genetic material, a fat, a carbohydrate, and a chemical compound: and
a fusing moiety linking the skin-penetrating peptide and the biologically active substance,
with the proviso that when the biologically active substance or the chemical compound is a protein, the skin-penetrating peptide and the biologically active substance are each derived from a peptide of different amino acid sequence, and the skin-penetrating peptide and the chemical compound are each derived from a peptide of different amino acid sequence.

2. The fusion product according to claim 1 , wherein the skin-penetrating peptide consists of 9-14 amino acid residues.

3. The fusion product according to claim 2 , wherein each of X1 and X3 is independently arginine or lysine.

4. The fusion product according to claim 2 , wherein X2 is alanine, tryptophan or arginine.

5. The fusion product according to claim 3 , which comprises the amino acid sequence of SEQ ID NO 1, SEQ ID NO 5, SEQ ID NO 8 or SEQ ID NO 12.

6. The fusion product according to claim 1 , wherein the biologically active substance is an rPTP peptide comprising the amino acid sequence of SEQ ID NO 20.

7. The fusion product according to claim 1 , which comprises the amino acid sequence of SEQ ID NO 19.

8. The fusion product according to claim 1 , wherein the linking by the fusing moiety is peptide bonding or chemical bonding.

9. The fusion product according to claim 8 , which wherein the chemical bonding is selected from a group consisting of disulfide bonding, diamine bonding, sulfide-amine bonding, carboxyl-amine bonding, ester bonding and covalent bonding.

10. A recombinant expression vector comprising a gene encoding the fusion product according to claim 1 .

11. A cosmetic composition comprising the fusion product of a skin-penetrating peptide and a biologically active substance according to claim 1 as an active ingredient.

12. The cosmetic composition according to claim 11 , which is prepared into a formulation selected from the group consisting of an emulsion, a cream, an essence, a skin lotion, a liposome, a microcapsule, a composite particle, a shampoo, and a rinse.

13. A pharmaceutical composition for external application to skin, comprising the fusion product of a skin-penetrating peptide and a biologically active substance according to claim 1 as an active ingredient.

14. The pharmaceutical composition for external application to skin according to claim 13 , wherein the biologically active substance fused with the skin-penetrating peptide penetrates the stratum corneum of skin.

15. A method for preventing or treating an inflammatory skin disease, comprising a step of applying an effective amount of the pharmaceutical composition for external application to skin according to claim 13 to the skin of a subject.

Assignees

• Iucf Hyu

Inventors

• Choi Je-Min
• Kim Wonju
• Koo Ja-Hyun
• Kim Jiyun

Classifications

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• A61Q19/00

  Preparations for care of the skin · CPC title

• C12Y301/03048

  Protein-tyrosine-phosphatase (3.1.3.48) · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K8/64

  Proteins; Peptides; Derivatives or degradation products thereof · CPC title